Skip to main content
TipRanks
Go Ultimate75% OFF

Stryker (SYK) AI Stock Analysis

2,782 Followers
SYK

Stryker

(NYSE:SYK)

Select Model
Rating:74Outperform
Price Target:$380.00▲(19.67% Upside)
Action:reiterated
Date:11/05/26

SYK scores well primarily on strong financial performance (robust growth, high margins, and improving leverage). The score is tempered by a rich valuation (high P/E, modest yield) and an earnings-call backdrop that includes a hip/knee slowdown and guidance reduction, while technicals remain constructive but appear near-term overbought.

Positive Factors
Diversified organic growthGrowth across both MedSurg and Neurotechnology and Orthopaedics demonstrates a broad revenue base rather than dependence on one product area. This diversification, supported by procedure-driven demand and international expansion, can improve resilience and sustain growth over the next several quarters.
Negative Factors
Hip and knee market slowdownSlower hip and knee procedure growth directly pressures one of Stryker’s important orthopaedic franchises. Affordability concerns, pre-authorization denials and regional softness may constrain volumes for several quarters, reducing the benefit of the company’s established implant and instrument positions.

Stryker Key Performance Indicators (KPIs)

Revenue by GeographyBreaks down Stryker’s revenue by region to show geographic concentration, sensitivity to local healthcare spending and procedure volumes, and which markets are fueling future expansion or posing risk.

$0.00$2.00B$4.00B$6.00BMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26Sep 26
Chart Insights

International revenue has been a steady growth engine, showing consistent seasonality but clear step‑up acceleration in the last two years that mirrors management’s reported ~9% international organic growth; this resilience helps offset U.S. vascular disruption and supports narrowed full‑year guidance. Near‑term risks include European procedure variability and staggered product ramps, but M&A (AVS), ongoing product launches and expected backlog resolution (Inari backorders manageable by end‑Q3) should sustain overseas momentum.

Data provided by:The Fly

Stryker (SYK) vs. SPDR S&P 500 ETF (SPY)

-30%-20%-10%0%10%20%SYK-10.94%SPY+11.73%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$120.88B
Dividend Yield
1.11%
Average Volume (3M)
2.92M
Price to Earnings (P/E)
33.6
Beta (1Y)
0.44
Revenue Growth
7.87%
EPS Growth
22.82%
Country
US
Employees
56,000
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Stryker Business Overview & Revenue Model

Company Description

Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including hip...

How the Company Makes Money

Stryker makes money primarily by selling medical devices, implants, and capital equipment to healthcare providers, generating revenue when products are delivered and accepted under customer contracts (with timing dependent on contract terms and appli...

Stryker Earnings Call Summary

Earnings Call Date:Oct 29, 2026(Q3-2026)|% Change Since:1.86%|Next Earnings Date:Feb 02, 2027
Earnings Call SentimentNeutral

The call was cautiously constructive but balanced. Stryker reported solid sales growth, adjusted EPS growth, margin expansion, strong cash generation, healthy capital demand, product momentum and a broad innovation and M&A pipeline. However, these positives were offset by a meaningful hip and knee market slowdown, weaker-than-expected commercial execution, Peripheral Vascular supply constraints and reduced full-year guidance. Management expressed confidence in the long-term outlook but acknowledged continued near-term uncertainty.

Positive Updates

Solid Third-Quarter Organic Sales Growth
Third-quarter organic sales grew 7.7%, including 9.1% growth in MedSurg and Neurotechnology and 5.9% growth in Orthopaedics. Endoscopy and Ortho Tech delivered double-digit performances, while Medical delivered near double-digit growth.

Negative Updates

Overall Results Fell Short of Expectations
Management stated that, despite solid growth in several businesses, overall third-quarter results fell short of expectations.

Company Guidance

Stryker’s updated guidance anticipates a similar overall organic growth rate for the company in Q4 as achieved in Q3, when organic sales growth was 7.7%, assuming a continuation of the procedure environment observed this quarter and continued strong capital demand; the company expects full year organic net sales growth of 6.5% to 7% and adjusted net earnings per share of $14.80 to $14.90, adjusted other income and expense of approximately $400 million, and a full year effective tax rate in the range of 15.5% to 16%. For Q4, Stryker expects strong growth for Trauma and Extremities, Medical to perform well, Instruments to have strong performances, and Peripheral Vascular to be a little bit better underlying; for 2027, while it will not provide formal guidance until early next year, it expects to deliver growth at the high end of our markets.

Stryker Financial Statement Overview

Summary

High-quality fundamentals supported by strong revenue expansion (≈$17.1B in 2021 to ≈$26.3B TTM), best-in-class gross margin (~66%), and solid operating profitability (operating margin ~21%, EBITDA margin ~25%). Balance sheet leverage is moderate and improving (debt-to-equity ~0.60 TTM), but absolute debt remains meaningful (~$14.2B). Cash generation is strong (TTM FCF ≈$4.6B) though FCF growth recently turned negative and cash conversion has been somewhat volatile.

Income Statement

86Very Positive

Balance Sheet

78Positive

Cash Flow

74Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue26.30B25.12B22.59B20.50B18.45B17.11B
Gross Profit17.23B16.07B14.54B12.49B11.04B10.71B
EBITDA6.62B6.31B6.01B5.06B4.02B3.61B
Net Income3.62B3.25B2.99B3.17B2.36B1.99B
Balance Sheet
Total Assets47.25B47.84B42.97B39.91B36.88B34.63B
Cash, Cash Equivalents and Short-Term Investments3.27B4.10B4.49B3.05B1.93B3.02B
Total Debt15.43B16.36B14.12B13.49B13.53B12.90B
Total Liabilities23.79B25.42B22.34B21.32B20.27B19.75B
Stockholders Equity23.46B22.42B20.63B18.59B16.62B14.88B
Cash Flow
Free Cash Flow4.57B4.28B3.49B3.14B2.04B2.74B
Operating Cash Flow5.45B5.04B4.24B3.71B2.62B3.26B
Investing Cash Flow-1.32B-4.87B-3.00B-962.00M-2.92B-859.00M
Financing Cash Flow-4.09B113.00M-525.00M-1.59B-749.00M-2.37B

Stryker Technical Analysis

Technical Analysis SentimentPositive
Last Price317.54

Price Trends

50DMA292.96Positive
100DMA309.85Positive
200DMA319.90Negative

Market Momentum

MACD5.97Positive
RSI55.61Neutral
STOCH14.28Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SYK, the sentiment is Positive. The current price of 317.54 is above the 20-day moving average (MA) of 313.20, above the 50-day MA of 292.96, and below the 200-day MA of 319.90, indicating a neutral trend. The MACD of 5.97 indicates Positive momentum. The RSI at 55.61 is Neutral, neither overbought nor oversold. The STOCH value of 14.28 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SYK.

Stryker Risk Analysis

Stryker disclosed 29 risk factors in its most recent earnings report. Stryker reported the most risks in the "Legal & Regulatory" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

0 New Risks

Stryker Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

SYK against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
MDTMDT81Outperform$130.88B25.1310.60%2.80%9.77%12.28%
SYKSYK74Outperform$120.88B33.6115.61%1.11%7.87%22.82%
GMEDGMED73Outperform$9.27B16.9911.82%―13.35%32.22%
SNNSNN69Neutral$12.72B20.0212.25%2.60%5.26%31.02%
ZBHZBH69Neutral$19.32B25.926.05%0.94%6.98%-2.22%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
IARTIART40Underperform$1.05B80.921.24%―0.84%―

* Healthcare Sector Average

Performance Comparison

-25%0%25%50%75%SYKIARTMDTSNNZBHGMEDDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SYK and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SYKStryker Corp317.54-42.70-11.85%
IARTIntegra Lifesciences13.552.4021.52%
MDTMedtronic102.325.205.35%
SNNSmith & Nephew Snats30.51-0.95-3.01%
ZBHZimmer Biomet Holdings102.0913.5915.35%
GMEDGlobus Medical69.99-13.83-16.50%

Stryker Corporate Events

Business Operations and StrategyExecutive/Board Changes

Stryker Announces CEO Succession and Leadership Transition

Positive
Oct 6, 2026

On October 6, 2026, Stryker announced a planned leadership succession in which long-serving Chief Executive Officer Kevin Lobo will resign as CEO on December 31, 2026 and become Executive Chair of the Board on January 1, 2027. Spencer Stiles, current...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 05, 2026